83% of pharma's trials published

More than eight out of 10 pharma-sponsored clinical trials made it into a peer-reviewed journal, a 23% increase over the 2008 rate, researchers showed.

Executives interviewed think the hike is likely driven by more stringent demands for investigators to publish, said research firm Cutting Edge Information.

Drug companies are holding investigators more accountable for publishing to journals, the firm said. Many write publication clauses in contracts, making final milestone payments conditional on publication of trial results.

One drug company no longer accepts proposals from investigators unwilling to agree to write trial data up for publication, Cutting Edge said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters